Andrzej Rostek
- Biohaven (NYSE:BHVN) is down ~5% Monday morning after results from a phase 3 trial of taldefgrobep alpha, its candidate for spinal muscular atrophy, failed to show a statistically significant difference vs. placebo in its primary outcome compared to placebo.
- Results
